

Psychiatric Comorbidity in Substance Abuse (Opioids)

B. Ahmad, K. A. Mufti, S. Farooq (Department of Psychiatry, Post Graduate Medical Institute, Lady Reading Hospital, Peshawar.)

Abstract

Objective: To find the prevalence of psychiatric disorders among the opioids dependents and to assess the severity of their addiction profile.

Method: Sample comprised of fifty patients admitted in drug treatment and rehabilitation center at Psychiatry Department of Lady Reading Hospital, Peshawar, between March to August 1997. DSM-IV diagnostic criteria were applied to diagnose substance dependence and associated psychiatric morbidity, while Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale and Addiction Severity Index were used to assess severity of anxiety, depression and dependence respectively.

Results: The major co-morbid psychiatric conditions were major depression (30%), personality disorder (6%), generalized anxiety disorder (4%), phobic disorder (4%), panic disorder (2%), dysthymic disorder (2%).

Conclusion: The overall findings in this study lends support to the hypothesis, that there is substantial psychiatric co-morbidity amongst the opioid abusers and dependents in our population, as is found in studies from the West (JPMA 51:183;2001).

Introduction

Substance abuse coexisting with other psychiatric disorders poses complex diagnostic and therapeutic challenges. Although the concept of co-morbidity is controversial¹ it provides useful conceptual framework. Co-morbidity is often associated with high rates of continued substance use, greater psychosocial impairment and increased utilization of services^{2,3}. Similarly the intervention for coexisting psychiatric morbidity may improve the outcome for the drug dependents⁴.

Studies of psychiatric co-morbidity in opioids abusers suggest that up to 80% patients meet the criteria for at least one non-substance use disorders during their life time⁵ while current disorders have been reported in 30%-70% of the patients^{6,7}. Mood disorders particularly depression and antisocial personality disorders are the commonest psychiatric diagnoses reported in patients dependents on opioids followed by dysthymia and anxiety disorders⁵. The variations in figures of co-existing psychiatric disorders is understandable in view of the widely different diagnostic criteria used, the different populations studied and different settings⁸. It is therefore very difficult to compare the studies which are carried out in different settings and the results cannot be generalized.

According to the United Nations International Narcotic Control Board report, the illicit cultivation, production and trafficking of the drugs almost always result in abuse amongst the local population where Pakistan's case has been quoted as the classic example where the number of substance abusers rose to an alarming 500,000 in the space of only 5 years⁹.

North West Frontier Province (NWFP) in Pakistan is the hub of poppy cultivation and drug trafficking activities. As a result it has gone through an epidemic of drug abuse particularly opioids. According to the national survey carried out in 1993 in Pakistan, there are more than 3.01 million substance abusers in Pakistan¹⁰. A thorough literature search on the subject found that there are only a few studies of incidence and prevalence and pattern of substance abuse in this part of the world. Based on retrospective record, coexisting psychiatric morbidity has one study in Pakistan⁹. Present study is therefore an attempt to find out the prevalence of psychiatric disorders in opioids abusers and its

correlates.

Patients and Methods

This study was carried out in drug treatment and rehabilitation center of psychiatry unit Lady Reading Hospital, Peshawar, Pakistan. The hospital is a teaching facility for Postgraduate Medical Institute Peshawar and is a tertiary referral center of the North West Frontier Province. The hospital catchment area extends well beyond North West Frontier Province into Afghanistan across the border. All the patients admitted between March and August 1997 meeting the D.S.M-IV criteria for substance abuse (opioid type) were included in the study. Diagnoses of psychiatric co-morbidity were made using Diagnostic and Statistical Manual (DSM-IV) diagnostic criteria laid down by American Psychiatric Association 1994¹¹. The patients above 65 years and below 15 years of age were excluded. Patients suffering from serious medical illness, having organic brain disease except with drug delirium and those who could not be assessed due to communication problem i.e., those Afghan speaking Persian and Turkmanistani languages were also excluded.

Mental state of patients was assessed with the help of Present State Examination (PSE)¹² two weeks after detoxification in the center. A close relative was also interviewed to gain further information about pattern and frequency of substance abuse. Severity of substance abuse was assessed with the help of Addiction Severity Index (ASI)¹³. It is an instrument that provides in a semi-structured interview, a multi-dimensional assessment of substance abuse patients. The scale was designed in 1980 by McLellon et al¹⁴ which provides assessment of problem severity in seven functional areas, in which substance abusers are commonly impaired and enable assessment of need for treatment. Severity of anxiety and depression was assessed with the help of Hamilton Anxiety Rating Scale (HARS) and Hamilton Depression Rating Scale (HDRS) respectively.

Results

The study was conducted between March and August 1997. During this period seventy patients of opioids abuse were admitted in the center. Thirteen patients were excluded due to concurrent physical disorder (pulmonary tuberculosis and acute bronchitis) while seven patients were out side the age limit defined for the study. Majority of the patients were male (98%), having mean age 27 years and unemployed or working in non-skilled jobs. Details of the demographic features are given in Table 1.

Table 1. Demographic features.

Demographic features	No.	%
Sex distribution		
Male	48	96
Female	2	4
Marital status		
Married	20	40
Unmarried	25	50
Separated	2	4
Widow/widower	3	6
Educated	34	68
No education	16	32
Unemployed	15	30
Employed	35	70

Psychiatric co-morbid disorders

Psychiatric disorders were found in 48% of patients. Majority of these patients had major depression i.e., 30% while rest of the patients had other psychiatric disorders (Table 2).

Table 2. Comorbid psychiatric disorder.

Psychiatric diagnosis	No.	%
Major depression	15	30
Personality disorder	3	6
Generalised anxiety disorders.	2	4
Phobic disorders	2	4
Panic disorders	1	2
Dysthymic disorders	1	2

On Hamilton Depression rating scale severity of the disorders were assessed in those patients who were found depressed on interview. Sixteen percent patients had scores in the range of moderate while fourteen percent in the range of severe depression, (Table 3).

Table 3. Score on Hamilton Depression Rating Scale.

HDRS Score	No. of patients.	%	Score
Absence of depressive episode	0	0	0-7
Minor depressive episode	8	16	8-16
Major depressive episode	7	14	17 and above

On Hamilton Anxiety rating scale, 16% patients had score in the range of mild anxiety while 4% in the range of severe anxiety. (Table 4),

Table 4. Score Hamilton Anxiety Rating scale.

HARS Score	No. of Patients	%	Score
Absence of anxiety state.	10	20	0-8
Symptoms of anxiety	8	16	9-20
Anxious state	2	4	21 and above

In the whole sample 26% patients were also using cannabis alongwith heroin while 4% patients were using alcohol and 2% patients were on tranquillisers alongwith heroin. Severity of dependence was assessed with the help of Addition Severity Index (ASI) (Table 5).

Table 5. Score Addiction Severity Index (ASI).

Score	1-3 (%)	4-7 (%)	8-10 (%)
Problem			
Medical	0	3	0
Employment/support status.	30	6	0
Alcohol/drug use	6	22	72
Legal Problems	96	04	0
Family/social relationship	56	18	26
Psychological status	58	26	16
Other addiction	70	20	12

Score: 1-3=0 severity ; 4-7=moderate severity; 8-10=highly severe.

Sixty two percent of the patients were abusing the substance for more than five years, with average intake of approximately 1.5 gram heroin per day. Sniffing was the most common route of administration i.e., 90% followed by oral and intravenous routes.

Discussion

This study has revealed interesting pattern of psychiatric co-morbidity in patients with opioids. It has to be noted that the sample size was small; population of the study from a tertiary care center may not be truly representative of opioids dependent in general and there was no control group to compare the psychiatric co-morbidity. Despite these limitations this study is an attempt to investigate the psychiatric comorbidity in an area which has experienced virtually an epidemic of opioid dependence.

In the present, study 24 patients (48%) had an additional psychiatric condition. This is in general agreement with most of the studies on the subject. For example Brooner et al^{15,8} reported psychiatric co-morbidity of 37%, 47% respectively. Similarly by Rouser et al¹⁶ reported that 39% patients had an additional psychiatric diagnosis. However Kessler et al⁷ reported about 50%, Dake et al¹⁷ 60% and Limbeek et al⁹ reported 85% additional psychiatric co-morbidity in their opioid dependent population. On the contrary Mericangas et al¹⁸ and Musharaf and Rehman⁹ reported less than 10% psychiatric co-morbidity in their samples. As discussed earlier there can be several reasons for these wide variations, including widely different population studied by different authors, use of different diagnostic criteria and the heterogeneous settings in which the studies were conducted. The relatively higher psychiatric morbidity in our sample can be attributed to a number of variables. One of the reasons seem to be, that the duration of drug dependence in this population was quite long, on an average about five years. It appears that psychiatric co-morbidity tends to accumulate with time probably due to the effects of the drugs on central nervous system and the resulting social and psychological complications.

Depression was the most commonly associated comorbid condition. Slightly less than one third (30%) of the patients had major depression. This is consistent with the findings of Limbeek et al⁶ and Regier et al¹⁹ while Rounsaville et al²⁰ reported a high figure of around 48% with major depression in their samples. Although Musharaf and Rehman⁹ reported a much lower figure of less than 2% in their study. It has to be noted that this was a retrospective study based on case notes which could have inherent problems. The findings of this study along with those of other studies, indicate that about one third of patients suffering from opioid dependence have additional depressive illness. These findings seem to lend support to the hypothesis of a relatively high prevalence of psychiatric co-morbidity among opioid dependents seeking treatment⁶.

In this population a much lower prevalence of anxiety disorders (panic anxiety, phobic disorder O.C.D), psychotic illnesses including mania, schizophrenia and personality disorder were found. Generally, anxiety and the psychotic disorder have been found to be less associated with opioid dependence^{8,9,19}. However comorbidity of schizophrenia and substance abuse has attracted considerable attention in recent years²¹ as the comorbidity of the two conditions is rapidly increasing²², Fowler et al²³ reported a higher prevalence of about 26% for overall substance abuse in schizophrenia however opioid has been reported in 2-9% only. Similarly Cantwell et al²⁴ showed that 7% of sample of 1st episode psychosis met the diagnosis of substance abuse including 8.4% with substance related psychotic disorder. There is agreement amongst most authors that substance abuse and schizophrenia are associated not only with violence but also with a number of other problems including poor treatment adherence, an increased suicide risk, increased rates of hospital admission and H.I.V infections²¹.

Similarly personality disorder has been found to be one of the common diagnostic category reported in studies especially from the Western countries. Personality disorder has been an additional diagnosis in excess of 30% in many studies^{6,15,16,17,19}. Dake et al even reported a figure of 60% in this study¹⁷. The low prevalence of personality disorder in our sample i.e., 6% is also in line with another study from our province⁹.

It appears that the low prevalence in this study is because the patients presented as self referrals to a teaching hospital unit. Mostly patients willing to receive help with some family support have probably

been referred to this service. The “hard core” addicts with some personality disorder might not have presented to our services. This is however an interesting finding and needs to be studied further with the help of standardized instruments to diagnose and measure the personality disorder in our population. This study highlights the high prevalence of psychiatric co-morbidity in patients with opioid dependents and its implication. Most common co-morbid psychiatric condition is major depression. This has important implications for prevention and management of substance dependence particularly the opioids. It appears that in clinical practice most of these cases go undetected even in the tertiary care units as was the case in this center. Proper treatment of depression can probably help to decrease the severity, duration and complications of drug dependence. It has been observed that an additional axis II diagnosis makes the outcome of the treatment of drug dependence more difficult¹⁵. The lower prevalence of personality disorder in our population is an encouraging indicator in the treatment and rehabilitation of this population.

It is evident that the sample had significant psychiatric comorbidity. Most common psychiatric disorder is major depression. In clinical practice most of these disorders go undetected even in the tertiary care centers. Detection and treatment of depression has significant primary and secondary preventive role in the management of substance dependence. So there is a need for screening all opioid dependents for psychiatric disorders who come for detoxification.

The high prevalence of psychiatric disorders in this study necessitates the screening of all opioid dependents, seeking treatment for psychiatric disorders and proper training of the staff working in the drug abuse treatment centers and a properly translated instrument to detect psychiatric morbidity.

References

1. Hansulrich W. Critical issues in the evaluation of comorbidity of Psychiatric disorders. Br. J. Psychiatry, 1996;168 (SupI-30):9-16.
2. Rounsaville B.J, Weissman MM, Christopher K, et al. Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch, Gen. Psychiatry, 1982;39: 151-56.
3. Li-Tzy Wu. Anthony C: Kouzis et al. Influence of comorbid alcohol and psychiatric disorders on utilisation of Mental Health Services in the National Comorbidity Survey. Am. J. Psychiatry, 1999;8:1230-36.
4. Rounsaville B.J. Kleber HO. Psychiatric disorders in opiate addicts, in R-E Myers Psychopathology and addictive disorders. New York. Oxford University Press, 1986;pp.140-168.
5. Robins Ln, Helzer JE, Weissman MM, et al. Life time prevalence of specific Psychiatric disorders in three sites. Arch. Gen. Psychiatry, 1985;41:949-58.
6. Liinbeek iv, Wouters L: Kaplan CD et al. Prevalence of Psychopathology in drug addicted Dutch. J. Subst. Abuse treat., 1992;9:43-52.
7. Kessler RC, Nelson CR, McGonagle KA, et al. The epidemiology of enoccurring addictive and mental disorders: implications for prevention and services utilisattion. Am. J. Orthopsychiatry, 1996;66: 17-31.
8. Brooner RK. Van L. King ci al. Psychiatric and substance use comorbidily among treatment seeking opioid abusers. Arch. Gen. Psychiatry. 1997;4: 71-80.
9. Khan M and Rehman A. Characteristics of heroin addiction in Peshawar. Pilot study. J. Postgrad Med. Inst (Peshawar) Pak, 1990;4: 80-86.
10. Planning Commission Government of Pakistan Islamabad. Report of sub committee on Mental Health and Substance abuse for 9th five year plan (1998-2003 AD) Islamabad Planing Comission, Govt, Pak, 1998;pp.4-7.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition (DSM-IV) 1994. Washington DC, Ain. Psvchiatr. Assoc., 994.
12. Wing JK, Cooper JE, Sartorius N. The measurement and classification of Psychiatric' symptoms.

An, Instructional Manual for the PSE and C A T F G 0. Programme. Cambridge University Press, 1974.pp.189-228.

13.Appleby L, Dyson V, Altmen E. et al. Assessing substance use in multiproblem patients: Reliability and Validity of the Addiction Severity Index. *J. Nerv. Ment. Dis.*, 1992;135: 159-165.

14.MC Lellan AT, Lubrosky L, Cacciola J et al New data from the Addition Severity Index: Reliability and validity in three centers. *J. Nerv. Ment Dis.*, 1985;135:412-23.

15.Erooner RK, Joffery H, Herbst AR et al. Antisocial Personality disorder among drug abusers. Relation to other Personality diagnosis and the five factor model of personality. *J. Nerv. Ment, Dis.*, 1993;181:313-19.

16.Rouser E, Brooner RK, Regier MW. Et al. Psychiatric disorders in antisocial drug abusers: Relation to other personality disorders. *Drug. Alcohol, Depend.*, 1994;34:149-54.

17.Dake S, Hall W, Swift W. Prevalence, symptoms and correlates of antisocial personality disorders among methadone maintenance clients. *Drug. Alcohol. Depend.*, 1994;34:253-57.

18.Merikangas KR, Rischl N, Weisman M. Comorbidity and co-transmission of affective disorders. *Psychol. Med.*, 1994;24:69-80.

19.Regier DA, Farmer M, Rae D et al. Comorbidity of mental disorders with alcohol and drug abuse, *JAMA.*, 1990;264: 2511-18.

20.Rounsaville B, Weissman MM, Kebler HO. Et al. Heterogeneity of Psychiatric diagnosis in treated opiate addicts. *Arch. Gen. Psychiatry.*, 1982;39:161-66.

21.Soyka M. Substance misuse, psychiatric disorders and violent and disturbed Behaviour, *Br. J. Psychiatry*, 2000;176: 345-50.

22.Boutrose MN, Bowers MR, Quinlan D. Chronological association between increase in drug abuse and psychosis in Connecticut State Hospitals. *J. Neuro psychiatr, Clin. Neurosci.*, 1998;10:48-54.

23.Fowler IL, Carr VC, Carter NT et al. Patients of current and life time substance use in schizophrenia. *Schizophrenia Bull.*, 1998;24:443-55.

24.Caniwell R, Brewin J, Glazebrook C et al. Prevalence of substance misuse in first episode psychosis. *Br. J. Psychiatry*, 1999;174:150-53.